Salta al contenido principal
evirtual
  • Página Principal
  • Más
En este momento está usando el acceso para invitados
Acceder
evirtual
Página Principal
Expandir todo Colapsar todo
  1. Garantía de Calidad de Medicamentos
  2. Material de Interés
  3. Impurezas Genotoxicas. Caso de las Nitrosaminas

Impurezas Genotoxicas. Caso de las Nitrosaminas

Requisitos de finalización
    • A Brief Review on Nitrosamine Impurity in Pharmaceuticals.pdf A Brief Review on Nitrosamine Impurity in Pharmaceuticals.pdf
    • A REVIEW ON NITROSAMINE IMPURITIES PRESENT IN DRUGS.pdf A REVIEW ON NITROSAMINE IMPURITIES PRESENT IN DRUGS.pdf
    • Analisis de nitrosaminas.pdf Analisis de nitrosaminas.pdf
    • Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea.pdf Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea.pdf
    • Consequences of New Approach to Chemical Stability Tests to Active Pharmaceutical Ingredients.pdf Consequences of New Approach to Chemical Stability Tests to Active Pharmaceutical Ingredients.pdf
    • Genotoxic Impurities in Ranitidine Containing Products An Overview.pdf Genotoxic Impurities in Ranitidine Containing Products An Overview.pdf
    • Identification and control of harmful impurities in pharmaceutical products.pdf Identification and control of harmful impurities in pharmaceutical products.pdf
    • Information Note Nitrosamine impurities.pdf Information Note Nitrosamine impurities.pdf
    • Is this the end for ranitidine NDMA presence continues to confound.pdf Is this the end for ranitidine NDMA presence continues to confound.pdf
    • Lab finds NDMA in Zantac can develop during storage _ Fierce Pharma.pdf Lab finds NDMA in Zantac can develop during storage _ Fierce Pharma.pdf
    • N-nitrosodimethylamine (NDMA) Contamination of Ranitidine.pdf N-nitrosodimethylamine (NDMA) Contamination of Ranitidine.pdf
    • Nitrosamine impurities in medicines_ History and challenges _ LGC Standards.pdf Nitrosamine impurities in medicines_ History and challenges _ LGC Standards.pdf
    • Nitrosated Active Pharmaceutical Ingredients – Lessons Learned_ - ScienceDirect.pdf Nitrosated Active Pharmaceutical Ingredients – Lessons Learned_ - ScienceDirect.pdf
    • Ranitidine A Proposed Mechanistic Rationale for NDMA formation.pdf Ranitidine A Proposed Mechanistic Rationale for NDMA formation.pdf
    • Ranitidine Products are Recalled Following Detection of Possibly Carcinogenic Substance.pdf Ranitidine Products are Recalled Following Detection of Possibly Carcinogenic Substance.pdf
    • Ranitidine Use and Incident Cancer in a Multinational Cohort.pdf Ranitidine Use and Incident Cancer in a Multinational Cohort.pdf
    • Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines.pdf Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines.pdf
    • Temperature-Dependent Formation of N-Nitrosodimethylamine during the Storage of Ranitidine.pdf Temperature-Dependent Formation of N-Nitrosodimethylamine during the Storage of Ranitidine.pdf
    • The Nitrosamine “Saga” Lessons Learned from Five Years of scrutiny.pdf The Nitrosamine “Saga” Lessons Learned from Five Years of scrutiny.pdf
En este momento está usando el acceso para invitados (Acceder)
Resumen de retención de datos
Desarrollado por Moodle
Moodle Appliance - Powered by TurnKey Linux